Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.

Gupta, Mehul; Stukalin, Igor; Meyers, Daniel; Goutam, Sid; Heng, Daniel Y C; Cheng, Tina; Monzon, Jose; Navani, Vishal

Gupta, Mehul; Stukalin, Igor; Meyers, Daniel; Goutam, Sid; Heng, Daniel Y C; Cheng, Tina; Monzon, Jose; Navani, Vishal.

Affiliation

Gupta M; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Stukalin I; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Meyers D; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Goutam S; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Heng DYC; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Cheng T; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Monzon J; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Navani V; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

JAMA Netw Open ; 6(6): e2319607, 2023 Jun 01.

Article de En | MEDLINE | ID: mdl-37351883

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Nivolumab / Mélanome Type d'étude: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limites: Aged / Humans / Male / Middle aged Pays/Région comme sujet: America do norte Langue: En Journal: JAMA Netw Open Année: 2023 Type de document: Article Pays d'affiliation: Canada Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google